Frequency (%) of Individual Marker Expression on B-LIN and T-LIN ALL
| Marker . | B-LIN (n = 206) . | T-LIN (n = 44) . |
|---|---|---|
| CD1+ | 0% | 63% |
| CD2+ | 6% | 70% |
| CD3+ | 0% | 41% |
| CD4+ | <1% | 61% |
| CD5+ | 1% | 84% |
| CD7+ | <1% | 93% |
| CD8+ | 0% | 55% |
| CD10+ | 72% | 16% |
| CD11c+ | 1% | 2% |
| CD13+ | 32% | 25% |
| CD19+ | 98% | 0% |
| CD20+ | 33% | 0% |
| CD22+ | 87% | 6% |
| CD33+ | 3% | 2% |
| CD34+ | 81% | 27% |
| CD38+ | 84% | 78% |
| HLA DR | 96% | 9% |
| κ+ | 1% | 0% |
| λ+ | 1.5% | 0% |
| IgD+ or IgM+ | 0%3-150 | 0%3-150 |
| Marker . | B-LIN (n = 206) . | T-LIN (n = 44) . |
|---|---|---|
| CD1+ | 0% | 63% |
| CD2+ | 6% | 70% |
| CD3+ | 0% | 41% |
| CD4+ | <1% | 61% |
| CD5+ | 1% | 84% |
| CD7+ | <1% | 93% |
| CD8+ | 0% | 55% |
| CD10+ | 72% | 16% |
| CD11c+ | 1% | 2% |
| CD13+ | 32% | 25% |
| CD19+ | 98% | 0% |
| CD20+ | 33% | 0% |
| CD22+ | 87% | 6% |
| CD33+ | 3% | 2% |
| CD34+ | 81% | 27% |
| CD38+ | 84% | 78% |
| HLA DR | 96% | 9% |
| κ+ | 1% | 0% |
| λ+ | 1.5% | 0% |
| IgD+ or IgM+ | 0%3-150 | 0%3-150 |
Four patients were B-LIN based on CD19 dim expression; 1 patient was not evaluable for CD19 but expressed CD20 and was thereby classified as B-LIN.
Surface IgD or IgM expression was found on 0 of 103 B-LIN and 0 of 18 T-LIN adult ALL cases evaluated.